Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
Moderna total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Moderna's total debt was $591.00M at Jun 30, 2026. For fiscal 2025 it was $590.00M.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $590.00M | – |
| FY2024 | Dec 31, 2024 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $591.00M | – |
| Q1 FY2026 | Mar 31, 2026 | $590.00M | – |
| Q4 FY2025 | Dec 31, 2025 | $590.00M | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
See a number that looks wrong?